Courage Therapeutics Inc Profile last edited on: 10/28/2021
CAGE: 8EUM2
UEI: W841GEJ8ADX7
Business Identifier: new medicines for eating disorders 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 04
County: Middlesex
Congr. District: 04
County: Middlesex
Public Profile
Courage Therapeutics Inc, spun out of the University of Michigan, develops therapeutics to treat eating disorders. The firm has expertise in melanocortin receptor biology and are identifying and commercializing peptides and small molecules for GPCR targets. Anorexia Nervosa is the primary eating disorder the firm is focused on, aiming to make recovery faster and easier.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 2 | NIH | $1,914,458 | |
| Project Title: Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss | ||||
| 2021 | 1 | NIH | $250,538 | |
| Project Title: Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa | ||||
Key People / Management
Dan Housman -- CEO
Roger Cone -- Founder
Fred Mermelstein
Tomui K Sawyer -- Head of Drug Discovery
Roger Cone -- Founder
Fred Mermelstein
Tomui K Sawyer -- Head of Drug Discovery
